公开(公告)号：EP1392676B1

公开(公告)日：2006-12-13

申请号：EP02714914.5

申请日：2002-02-15

申请人： AVENTIS PHARMACEUTICALS INC.

发明人： HENDRIX, James, A. ,  STRUPCZEWSKI, Joseph, T. ,  BORDEAU, Kenneth, J. ,  BROOKS, Sarah ,  HEMMERLE, Horst ,  URMANN, Matthias ,  ZHAO, Xu-Yang ,  MUELLER, Paul, Justin.

IPC分类号： C07D333/62 ,  C07D333/54 ,  C07D498/04 ,  C07D495/04 ,  A61K31/381 ,  A61P25/18

CPC分类号： C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D333/66 ,  C07D451/02 ,  C07D495/04

摘要： The invention relates to heterocyclic substituted urea derivatives of the formula (I) that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D3 receptors.

公开(公告)号：EP1361875A2

公开(公告)日：2003-11-19

申请号：EP02721057.4

申请日：2002-02-15

申请人： Aventis Pharmaceuticals Inc.

发明人： HENDRIX, James, A. ,  STRUPCZEWSKI, Joseph, T. ,  BORDEAU, Kenneth, J. ,  URMANN, Matthias ,  SHUTSKE, Gregory ,  HEMMERLE, Horst ,  JURCAK, John, G. ,  GILL, Harpal ,  WEIBERTH, Franz, Jr. ,  NIEDUZAK, Thaddeus ,  JACKSON, Sharon, A. ,  ZHAO, Xu-Yang ,  MUELLER, Paul J.

IPC分类号： A61K31/33

CPC分类号： C07D249/08 ,  C07D231/12 ,  C07D233/56 ,  C07D333/58 ,  C07D333/66 ,  C07D333/68 ,  C07D333/70 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D451/02 ,  C07D471/04 ,  C07D495/04

摘要： The invention relates to heterocyclic substituted amide derivatives of formula (I) that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D3 receptors.

公开(公告)号：EP1392676A2

公开(公告)日：2004-03-03

申请号：EP02714914.5

申请日：2002-02-15

申请人： Aventis Pharmaceuticals, Inc.

发明人： HENDRIX, James, A. ,  STRUPCZEWSKI, Joseph, T. ,  BORDEAU, Kenneth, J. ,  BROOKS, Sarah ,  HEMMERLE, Horst ,  URMANN, Matthias ,  ZHAO, Xu-Yang ,  MUELLER, Paul, Justin.

IPC分类号： C07D333/62 ,  C07D333/54 ,  C07D498/04 ,  C07D495/04 ,  A61K31/381 ,  A61P25/18

CPC分类号： C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D333/66 ,  C07D451/02 ,  C07D495/04

摘要： The invention relates to heterocyclic substituted urea derivatives of the formula (I) that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D3 receptors.

公开(公告)号：EP1216244B1

公开(公告)日：2003-08-13

申请号：EP00963370.2

申请日：2000-09-13

申请人： Aventis Pharmaceuticals Inc.

发明人： SHUTSKE, Gregory, M. ,  HENDRIX, James, A. ,  JURCAK, John, G. ,  FREED, Brian, S. ,  HRIB, Nicholas, J. ,  TOMER, John, D., IV ,  HANNA, Reda, G.

IPC分类号： C07D413/12 ,  C07D261/20 ,  C07D413/14 ,  C07D471/04 ,  C07D409/14 ,  C07D333/56 ,  C07D409/12 ,  C07D498/04 ,  A61K31/42 ,  A61K31/38 ,  A61K31/47 ,  A61K31/44 ,  C07D213/61 ,  C07C251/48

CPC分类号： C07D409/12 ,  C07C251/48 ,  C07D261/20 ,  C07D333/56 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D491/10

公开(公告)号：EP1216244A1

公开(公告)日：2002-06-26

申请号：EP00963370.2

申请日：2000-09-13

申请人： Aventis Pharmaceuticals Inc.

发明人： SHUTSKE, Gregory, M. ,  HENDRIX, James, A. ,  JURCAK, John, G. ,  FREED, Brian, S. ,  HRIB, Nicholas, J. ,  TOMER, John, D., IV ,  HANNA, Reda, G.

IPC分类号： C07D413/12 ,  C07D261/20 ,  C07D413/14 ,  C07D471/04 ,  C07D409/14 ,  C07D333/56 ,  C07D409/12 ,  C07D498/04 ,  A61K31/42 ,  A61K31/38 ,  A61K31/47 ,  A61K31/44 ,  C07D213/61 ,  C07C251/48

CPC分类号： C07D409/12 ,  C07C251/48 ,  C07D261/20 ,  C07D333/56 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D491/10

摘要： The compounds are of the class of benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.